Novel obesity drug induces up to 22% weight loss with no safety concerns

Subcutaneous amycretin featured a safety profile similar to other incretin-based drugs in a phase 1b/2a trial. Adults with obesity lost more weight with 1.25 mg, 5 mg and 20 mg amycretin vs. placebo.

Read More

Source: Healio